| Leukemia, Myelocytic, Acute
Neupogen vs Rezlidhia
Side-by-side clinical, coverage, and cost comparison for leukemia, myelocytic, acute.Deep comparison between: Neupogen vs Rezlidhia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRezlidhia has a higher rate of injection site reactions vs Neupogen based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rezlidhia but not Neupogen, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Neupogen
Rezlidhia
At A Glance
SC injection
Daily
G-CSF
Oral
Twice daily
IDH1 inhibitor
Indications
- Febrile Neutropenia
- Leukemia, Myelocytic, Acute
- Neutropenia
- Severe congenital neutropenia
- Cyclic neutropenia
- Idiopathic neutropenia
- Hematopoietic subsyndrome of acute radiation syndrome
- Leukemia, Myelocytic, Acute
Dosing
Febrile Neutropenia, Leukemia, Myelocytic, Acute 5 mcg/kg/day SC injection, short IV infusion (15-30 min), or continuous IV infusion; administer at least 24 hours after cytotoxic chemotherapy.
Neutropenia (bone marrow transplantation) 10 mcg/kg/day IV infusion no longer than 24 hours; administer at least 24 hours after cytotoxic chemotherapy and bone marrow infusion.
Autologous PBPC collection 10 mcg/kg/day SC injection; administer for at least 4 days before first leukapheresis and continue until last leukapheresis.
Severe congenital neutropenia 6 mcg/kg SC injection twice daily.
Cyclic neutropenia, Idiopathic neutropenia 5 mcg/kg SC injection daily.
Hematopoietic subsyndrome of acute radiation syndrome 10 mcg/kg/day SC injection; administer as soon as possible after suspected or confirmed exposure to radiation doses >2 Gy.
Leukemia, Myelocytic, Acute 150 mg orally twice daily until disease progression or unacceptable toxicity; take on an empty stomach at least 1 hour before or 2 hours after a meal.
Contraindications
- History of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim or pegfilgrastim
—
Adverse Reactions
Most common (>=5%) Pyrexia, nausea, fatigue, thrombocytopenia, bone pain, back pain, rash, dizziness, cough, dyspnea, chest pain, arthralgia
Serious Splenic rupture, acute respiratory distress syndrome, serious allergic reactions, sickle cell disorders, glomerulonephritis, alveolar hemorrhage and hemoptysis, capillary leak syndrome, myelodysplastic syndrome, acute myeloid leukemia, thrombocytopenia, leukocytosis, cutaneous vasculitis, aortitis
Postmarketing Splenic rupture, splenomegaly, anaphylaxis, sickle cell disorders, glomerulonephritis, alveolar hemorrhage and hemoptysis, capillary leak syndrome, leukocytosis, cutaneous vasculitis, Sweet's syndrome, decreased bone density and osteoporosis, myelodysplastic syndrome, acute myeloid leukemia, aortitis, extramedullary hematopoiesis
Most common (>=20%) AST increased, ALT increased, potassium decreased, sodium decreased, alkaline phosphatase increased, nausea, creatinine increased, fatigue/malaise, arthralgia, constipation, lymphocytes increased, bilirubin increased, leukocytosis, uric acid increased, dyspnea, pyrexia, rash, lipase increased, mucositis, diarrhea, transaminitis
Serious Differentiation syndrome, transaminitis
Pharmacology
Filgrastim is a recombinant human G-CSF that binds to specific cell surface receptors on hematopoietic cells, stimulating neutrophil progenitor proliferation and differentiation and enhancing end-cell functional activities including phagocytic ability, respiratory burst priming, and antibody-dependent killing.
Olutasidenib is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1); it inhibits mutant IDH1 proteins (R132H, R132C, and others), reducing 2-hydroxyglutarate (2-HG) levels in leukemia cells and promoting differentiation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Neupogen
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (6/12) · Qty limit (0/12)
Rezlidhia
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Neupogen
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Rezlidhia
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Neupogen
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (1/3)
Rezlidhia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Acute Myeloid Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$15/fillfill
Rezlidhia CoPay AssistanceCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NeupogenView full Neupogen profile
RezlidhiaView full Rezlidhia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.